Carboplatin injection is indicated for the initial treatment of advanced epithelial ovarian carcinoma, usually in combination with other approved chemotherapy agents. It is also indicated for the palliative treatment of patients with ovarian cancer that has recurred after previous chemotherapy.

Carboplatin is a platinum-based alkylating agent that forms covalent bonds with DNA. By binding to DNA, it produces DNA cross-links, which disrupt the normal structure and function of DNA. This interference prevents proper DNA replication and transcription, thereby inhibiting cell division and leading to the death of rapidly dividing cancer cells.

Needles or intravenous sets containing aluminum parts that may come in contact with Carboplatin injection should not be used for the preparation or administration. Aluminum reacts with Carboplatin causing precipitate formation and/or loss of potency. Procedures for proper handling and disposal of anti-cancer drugs should be implemented. Several guidelines on this subject have been published. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

After dilution, Carboplatin should be used by the intravenous route only. The recommended dosage of Carboplatin in previously untreated adult patients with normal kidney function is 400 mg/m² as a single I.V. dose administered by a 15 to 60 minute infusion. Therapy should not be repeated until four weeks after the previous Carboplatin course and/or until the neutrophil count is at least 2000 cells/mm³ and the platelet count is at least 100,000 cells/mm³. Reduction of the initial dosage by 20–25% (i.e, 300–320 mg/m²) is recommended for those patients who present with risk factors such as prior myelosuppressive treatment and low performance status (ECOG-Zubrod 2–4 or Karnofsky below 80). For patients age 65 and over, dosage adjustment, initially or subsequently, may be necessary, dependent on the physical condition of the patient.

Determination of the hematologic nadir by weekly blood count during the initial courses of treatment with Carboplatin is recommended for dosage adjustment for subsequent courses of therapy.

Carboplatin should not be mixed with other medications in the same infusion solution. Concomitant use with nephrotoxic or neurotoxic agents may enhance the toxic effects on the kidneys or nervous system. Therefore, caution should be exercised when Carboplatin is administered alongside drugs that have similar toxic effects.

Carboplatin should not be used in patients with: Severe renal impairment, unless the potential benefit outweighs the risks Severe bone marrow suppression (myelosuppression). Known hypersensitivity to Carboplatin, other platinum compounds, or mannitol, Bleeding tumors.

The adverse reactions of Carboplatin are primarily related to bone marrow suppression, which is the major dose-limiting toxicity.

Hematologic toxicity:  Bone marrow suppression is the most common adverse effect. It may lead to: Thrombocytopenia (low platelet count) in about 25% of patients. Neutropenia in approximately 18% of patients, Leucopenia in about 14% of patients, Anemia in approximately 71% of patients. The lowest blood cell counts usually occur 14–21 days after treatment, with recovery occurring within several weeks. Patients with kidney dysfunction, previous intensive chemotherapy, or older age may experience more severe myelosuppression.

Renal toxicity: Abnormal kidney function is relatively uncommon but may occur. Mild increases in serum creatinine, blood urea nitrogen, or uric acid may be observed. Electrolyte disturbances such as reduced sodium, potassium, calcium, or magnesium levels have also been reported.

Gastrointestinal toxicity:  Nausea occurs in about 15% of patients, Vomiting occurs in about 65% of patients, Other symptoms include abdominal pain, diarrhea, constipation, and loss of appetite.

Allergic reactions:  Hypersensitivity reactions are uncommon but may include rash, fever, itching, urticaria, bronchospasm, or hypotension.

Hepatic toxicity: Abnormal liver function tests such as elevated bilirubin, AST, or alkaline phosphatase may occur but are usually mild and reversible.

Neurotoxicity: Peripheral neuropathy may occur in a small number of patients and may cause tingling sensations (paresthesia) or reduced reflexes. These effects are more common in patients previously treated with Cisplatin.

Carboplatin is classified as Pregnancy Category D. Adequate studies in pregnant women are not available, but the drug may pose a risk to the fetus. Carboplatin has been detected in human breast milk; therefore, breastfeeding should generally be avoided during treatment.

Carboplatin should only be administered by a physician experienced in cancer chemotherapy. Regular monitoring of blood counts, kidney function, and liver function is essential during treatment. Treatment cycles should generally not be repeated more frequently than once per month. Patients receiving Carboplatin may experience dose-dependent thrombocytopenia, leucopenia, and anemia, therefore frequent monitoring of peripheral blood counts is necessary.

Combination therapy with other myelosuppressive drugs should be planned carefully to minimize additive toxicity. Severe myelosuppression may require supportive transfusion therapy. Antiemetic medications may help reduce nausea and vomiting associated with Carboplatin therapy. In addition, allergic reactions may occur shortly after infusion and should be treated promptly.

Cytotoxic Chemotherapy

Store below 25°C in a dry place. Do not refrigerate. Keep out of the reach of children.